Literature DB >> 17878422

Association of apolipoprotein E genotypes with lipid levels and coronary risk.

Anna M Bennet1, Emanuele Di Angelantonio, Zheng Ye, Frances Wensley, Anette Dahlin, Anders Ahlbom, Bernard Keavney, Rory Collins, Björn Wiman, Ulf de Faire, John Danesh.   

Abstract

CONTEXT: Previous reviews of associations of apolipoprotein E (apoE) genotype and coronary disease have been dominated by smaller studies that are liable to biases.
OBJECTIVE: To reassess associations of apoE genotypes with circulating lipid levels and with coronary risk. DATA SOURCES: We conducted an updated meta-analysis including both published and previously unreported studies, using MEDLINE, EMBASE, BIOSIS, Science Citation Index, and the Chinese National Knowledge Infrastructure Database published between January 1970 and January 2007, reference lists of articles retrieved, and a registry of relevant studies. STUDY SELECTION: Eighty-two studies of lipid levels (86,067 healthy participants) and 121 studies of coronary outcomes (37,850 cases and 82,727 controls) were identified, with prespecified principal focus on studies with at least 1000 healthy participants for lipids and those with at least 500 coronary outcomes. DATA EXTRACTION: Information on genotype frequencies, lipid levels, coronary outcomes, and laboratory and population characteristics were recorded independently by 2 investigators and/or supplied by study investigators.
RESULTS: In the most extreme comparison, people with the epsilon2/epsilon2 genotype had 1.14 mmol/L (95% confidence interval [CI], 0.87-1.40 mmol/L [44.0 mg/dL; 95% CI; 33.6-51.1 mg/dL]) or about 31% (95% CI, 23%-38%) lower mean low-density lipoprotein cholesterol (LDL-C) values than those with the epsilon4/epsilon4 genotype. There were approximately linear relationships of apoE genotypes (when ordered epsilon2/epsilon2, epsilon2/epsilon3, epsilon2/epsilon4, epsilon3/epsilon3, epsilon3/epsilon4, epsilon4/epsilon4) with LDL-C and with coronary risk. The relationship with high-density lipoprotein cholesterol was inverse and shallow and that with triglycerides was nonlinear and largely confined to the epsilon2/epsilon2 genotype. Compared with epsilon3/epsilon3, the odds ratio for coronary disease was 0.80 (95% CI, 0.70-0.90) in epsilon2 carriers and was 1.06 (95% CI, 0.99-1.13) in epsilon4 carriers.
CONCLUSIONS: There are approximately linear relationships of apoE genotypes with both LDL-C levels and coronary risk. Compared with individuals with the epsilon3/epsilon3 genotype, epsilon2 carriers have a 20% lower risk of coronary heart disease and epsilon4 carriers have a slightly higher risk.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17878422     DOI: 10.1001/jama.298.11.1300

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  271 in total

1.  Mining relational paths in integrated biomedical data.

Authors:  Bing He; Jie Tang; Ying Ding; Huijun Wang; Yuyin Sun; Jae Hong Shin; Bin Chen; Ganesh Moorthy; Judy Qiu; Pankaj Desai; David J Wild
Journal:  PLoS One       Date:  2011-12-06       Impact factor: 3.240

2.  Interaction of occupational and personal risk factors in workforce health and safety.

Authors:  Paul A Schulte; Sudha Pandalai; Victoria Wulsin; HeeKyoung Chun
Journal:  Am J Public Health       Date:  2011-11-28       Impact factor: 9.308

3.  Aging genetics and aging.

Authors:  Sandra Rodríguez-Rodero; Juan Luis Fernández-Morera; Edelmiro Menéndez-Torre; Vincenzo Calvanese; Agustín F Fernández; Mario F Fraga
Journal:  Aging Dis       Date:  2011-04-28       Impact factor: 6.745

4.  Prevalence of apolipoprotein E epsilon4 allele may explain the geographical variation of coronary heart disease mortality rates in Western Europe.

Authors:  William B Grant
Journal:  Eur J Epidemiol       Date:  2010-07-29       Impact factor: 8.082

5.  Impaired adipogenic response to thiazolidinediones in mice expressing human apolipoproteinE4.

Authors:  Jose M Arbones-Mainar; Lance A Johnson; Michael K Altenburg; Hyung-Suk Kim; Nobuyo Maeda
Journal:  FASEB J       Date:  2010-05-25       Impact factor: 5.191

6.  Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study.

Authors:  Marguerite R Irvin; Edmond K Kabagambe; Hemant K Tiwari; Laurence D Parnell; Robert J Straka; Michael Tsai; Jose M Ordovas; Donna K Arnett
Journal:  Circ Cardiovasc Genet       Date:  2010-08-21

7.  Effect of 10 different polymorphisms on preoperative volumetric characteristics of glioblastoma multiforme.

Authors:  Christian Henker; Thomas Kriesen; Katharina Fürst; Deborah Goody; Änne Glass; Brigitte M Pützer; Jürgen Piek
Journal:  J Neurooncol       Date:  2015-11-25       Impact factor: 4.130

8.  Association of APOE polymorphisms with diabetes and cardiometabolic risk factors and the role of APOE genotypes in response to anti-diabetic therapy: results from the AIDHS/SDS on a South Asian population.

Authors:  Bishwa Sapkota; Anuradha Subramanian; Gargi Priamvada; Hadley Finely; Piers R Blackett; Christopher E Aston; Dharambir K Sanghera
Journal:  J Diabetes Complications       Date:  2015-08-01       Impact factor: 2.852

9.  High serum apolipoprotein E determines hypertriglyceridemic dyslipidemias, coronary disease and apoA-I dysfunctionality.

Authors:  Altan Onat; Günay Can; Ender Ornek; Erkan Ayhan; Nihan Erginel-Ünaltuna; Sani N Murat
Journal:  Lipids       Date:  2012-10-25       Impact factor: 1.880

10.  Replication of genetic associations with plasma lipoprotein traits in a multiethnic sample.

Authors:  Matthew B Lanktree; Sonia S Anand; Salim Yusuf; Robert A Hegele
Journal:  J Lipid Res       Date:  2009-03-18       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.